Physician
Oncology
Dr. Adrian M. Senderowicz, MD
|
|
Give Review
Dr. Adrian M. Senderowicz is an expert in the field of Oncology. He studied medicine at Mount Sinai School of Medicine. Adrian Senderowicz is also a published doctor. He has 85 publication published. The most recent publication is: UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
Publications
- A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
- Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.
- Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).
- CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development.
- S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells.
- Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
- Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1.
- RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
- Targeting cell cycle and apoptosis for the treatment of human malignancies.
- Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.
- UCN-01-induced cell cycle arrest requires the transcriptional induction of p21(waf1/cip1) by activation of mitogen-activated protein/extracellular signal-regulated kin...
- Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
- Assays for cyclin-dependent kinase inhibitors.
- Cell cycle modulators for the treatment of lung malignancies.
- Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.
- Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.
- Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
- Alsterpaullone, a novel cyclin-dependent kinase inhibitor, induces apoptosis by activation of caspase-9 due to perturbation in mitochondrial membrane potential.
- Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.
- Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).
- Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.
- Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
- Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent ...
- Second symposium of novel molecular targets for cancer therapy.
- The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
- Expression of CDK4 or CDK2 in mouse oral cavity is retained in adult pituitary with distinct effects on tumorigenesis.
- Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.
- Transcriptional activation of p21(waf1/cip1) by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21(waf1/c...
- Jasplakinolide, a cytotoxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin.
- Jasplakinolide's inhibition of the growth of prostate carcinoma cells in vitro with disruption of the actin cytoskeleton.
- Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
- Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25.
- Induction of growth inhibition and apoptosis in prostate cancer cells by flavopiridol.
- Complete sustained response of a refractory, post-transplantation, large B-cell lymphoma to an anti-CD22 immunotoxin.
- An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript.
- Sodium polystyrene sulfonate damage.
- Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol.
- Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
- Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein.
- Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
- Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases.
- UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.
- Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
- Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models.
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
- Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
- Metabolism of the anticancer drug flavopiridol, a new inhibitor of cyclin dependent kinases, in rat liver.
- Inhibition of CDKs as a therapeutic modality.
- Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.
- A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), C...
- Preclinical and clinical development of cyclin-dependent kinase modulators.
- Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: presentation of a novel therapeutic paradigm.
- Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
- Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol.
- A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
- Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes.
- Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.
- Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
- Small molecule modulators of cyclin-dependent kinases for cancer therapy.
- Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.
- First symposium of novel molecular targets for cancer therapy.
- Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.
- Histone acetylation and the cell-cycle in cancer.
- In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.
- Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies.
- Possible mechanisms of diarrheal side effects associated with the use of a novel chemotherapeutic agent, flavopiridol.
- Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
- Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior a...
- Antiproliferative effect in vitro and antitumor activity in vivo of brefeldin A.
- Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
- A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma.
- Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.
- P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228.
- Cardiovascular autonomic function in anthracycline-treated breast cancer patients.
- Cyclin-dependent kinases as targets for cancer therapy.
- Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
- Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).
- Small-molecule cyclin-dependent kinase modulators.
- The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.
- Role of cell cycle control and cyclin-dependent kinases in breast cancer.
- Inhibitors of cyclin-dependent kinase modulators for cancer therapy.
- Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.
Schools
University of Buenos Aires Faculty of Medicine
Booth Meml Hospital Center
Mt Sinai Hospital
National Cancer Institute
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Mount Sinai School of Medicine -
New York Hospital Medical Center of Queens -
University of Buenos Aires
Helpful Reviews
Similar Doctors
|
|
Louis M. Staudt |
|
|
Dr. Richard Piekarz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip M. Arlen, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Alain Thibault, MD |
|
|
Dr. Howard L. Parnes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Geoffrey S. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher S. Hourigan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christian S. Hinrichs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard W. Childs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice P. Chen, MD |
|
|
Dr. Gregory A. Curt, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Samuel Broder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elisabet Manasanch, MD |
|
|
Giuseppe Giaccone
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Jaye L. Viner, MD
This Doctor is OpenDoctor Recommended.
|